Sonia Iyer
AstraZeneca (United States)(US)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, CRISPR and Genetic Engineering, PARP inhibition in cancer therapy, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → SHIP1 Inhibition Increases Immunoregulatory Capacity and Triggers Apoptosis of Hematopoietic Cancer Cells(2010)140 cited
- → Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy(2020)131 cited
- → Therapeutic Potential of SH2 Domain-Containing Inositol-5′-Phosphatase 1 (SHIP1) and SHIP2 Inhibition in Cancer(2011)111 cited
- → Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial(2024)108 cited
- → Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer(2020)87 cited
- → Inaugurating High‐Throughput Profiling of Extracellular Vesicles for Earlier Ovarian Cancer Detection(2023)50 cited
- → The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment(2024)44 cited
- → Role of SHIP1 in cancer and mucosal inflammation(2013)40 cited
- → Layer‐by‐layer interleukin‐12 nanoparticles drive a safe and effective response in ovarian tumors(2022)35 cited
- → Coordinate Expansion of Murine Hematopoietic and Mesenchymal Stem Cell Compartments by SHIPi(2015)34 cited